JMP Securities Initiates Coverage on OptimizeRx (NASDAQ:OPRX)

JMP Securities began coverage on shares of OptimizeRx (NASDAQ:OPRX) in a research report issued on Thursday, Marketbeat reports. The brokerage set a “mkt outperform” rating and a $15.00 price target on the stock. JMP Securities’ price target would suggest a potential upside of 31.93% from the company’s previous close.

A number of other analysts also recently issued reports on OPRX. Barclays assumed coverage on shares of OptimizeRx in a report on Wednesday, January 3rd. They set an “equal weight” rating and a $15.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of OptimizeRx in a report on Monday, April 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price target on shares of OptimizeRx in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.86.

OptimizeRx Trading Up 1.4 %

Shares of NASDAQ OPRX opened at $11.37 on Thursday. The firm has a fifty day simple moving average of $14.13 and a two-hundred day simple moving average of $11.77. The firm has a market capitalization of $206.37 million, a PE ratio of -14.21 and a beta of 0.98. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65.

Insider Buying and Selling

In other OptimizeRx news, General Counsel Marion Odence-Ford sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $15.19, for a total transaction of $60,760.00. Following the sale, the general counsel now owns 11,114 shares in the company, valued at approximately $168,821.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OptimizeRx

Several large investors have recently bought and sold shares of OPRX. Thrivent Financial for Lutherans boosted its stake in shares of OptimizeRx by 4.5% during the third quarter. Thrivent Financial for Lutherans now owns 18,631 shares of the company’s stock valued at $276,000 after purchasing an additional 797 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of OptimizeRx by 1.7% during the third quarter. Nuveen Asset Management LLC now owns 49,959 shares of the company’s stock valued at $741,000 after acquiring an additional 842 shares in the last quarter. Captrust Financial Advisors boosted its position in OptimizeRx by 248.8% in the second quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock valued at $35,000 after buying an additional 918 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in OptimizeRx by 2.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 45,103 shares of the company’s stock valued at $1,701,000 after buying an additional 1,033 shares during the last quarter. Finally, Point72 Hong Kong Ltd boosted its position in OptimizeRx by 81.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 2,492 shares of the company’s stock worth $68,000 after purchasing an additional 1,120 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.